Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-2: Naltrexone plus Bupropion for Methamphetamine Use Disorder
NCT03078075Phase 3Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone, bupropion in methamphetamine use disorder (MUD), sponsored by UT Southwestern Medical Center. Started May 2017; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT03078075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078075.